Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease

Vaccine

Volumn 30, Issue 5, 2012, Pages 931-935

  Zitt, Emanuel ^a,b   Sprenger Mähr, Hannelore ^a,b   Knoll, Florian ^a   Neyer, Ulrich ^a,b   Lhotta, Karl ^a,b  

^a ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^b Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

Author keywords

Chronic kidney disease; Hepatitis B; Vaccination; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; VITAMIN D DERIVATIVE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMIN D DEFICIENCY;

EID: 84855422355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.086     Document Type: Article

References (36)

1. Kausz A., Pahari D. The value of vaccination in chronic kidney disease. Semin Dial 2004, 17:9-11.
2. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984, 311:496-501.
3. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J.A., Bartolome J., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992, 12:144-147.
4. Eleftheriadis T., Antoniadi G., Liakopoulos V., Kartsios C., Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20:440-451.
5. LaClair R.E., Hellman R.N., Karp S.L., Kraus M., Ofner S., Li Q., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005, 45:1026-1033.
6. Mehrotra R., Kermah D., Budoff M., Salusky I.B., Mao S.S., Gao Y.L., et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1144-1151.
7. Ginde A.A., Liu M.C., Camargo C.A. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009, 169:626-632.
8. Blair D., Byham-Gray L., Lewis E., McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008, 18:375-382.
9. Drechsler C., Verduijn M., Pilz S., Dekker F.W., Krediet R.T., Ritz E., et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011, 26:1024-1032.
10. Pilz S., Tomaschitz A., Friedl C., Amrein K., Drechsler C., Ritz E., et al. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011, 10.1093/ndt/gfr076.
11. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
12. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000, 374:334-338.
13. Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008, 8:685-698.
14. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. http://www.cdcgov/vaccines/Pubs/downloads/b_dialysis_guide-508pdf.
15. WHO WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteopoosis: Report of a WHO scientific group 2003.
16. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
17. Williams B., Williams A.J., Anderson S.T. Vitamin D deficiency and insufficiency in children with tuberculosis. Pediatr Infect Dis J 2008, 27:941-942.
18. Ginde A.A., Mansbach J.M., Camargo C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009, 169:384-390.
19. Martineau A.R., Timms P.M., Bothamley G.H., Hanifa Y., Islam K., Claxton A.P., et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011, 377:242-250.
20. Cantorna M.T., Yu S., Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. Mol Aspects Med 2008, 29:369-375.
21. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004, 229:1136-1142.
22. Prietl B., Pilz S., Wolf M., Tomaschitz A., Obermayer-Pietsch B., Graninger W., et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?. Isr Med Assoc J 2010, 12:136-139.
23. Enioutina E.Y., Bareyan D., Daynes R.A. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 2008, 26:601-613.
24. Enioutina E.Y., Bareyan D., Daynes R.A. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. J Immunol 2009, 182:4296-4305.
25. Fabrizi F., Dixit V., Martin P., Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011, 33:815-821.
26. Chadha M.K., Fakih M., Muindi J., Tian L., Mashtare T., Johnson C.S., et al. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate 2011, 71:368-372.
27. Kriesel J.D., Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine 1999, 17:1883-1888.
28. Dusso A.S., Finch J., Brown A., Ritter C., Delmez J., Schreiner G., et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991, 72:157-164.
29. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, S1-S130.
30. Kalantar-Zadeh K., Kovesdy C.P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1529-1539.
31. Huzly D., Schenk T., Jilg W., Neumann-Haefelin D. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008, 46:1298-1306.
32. DaRoza G., Loewen A., Djurdjev O., Love J., Kempston C., Burnett S., et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003, 42:1184-1192.
33. Fabrizi F., Dixit V., Messa P., Martin P. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. J Viral Hepat 2011, 18:730-737.
34. Fabrizi F., Dixit V., Messa P., Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment Pharmacol Ther 2010, 32:756-762.
35. Surquin M., Tielemans C.L., Kulcsar I., Ryba M., Voros P., Mat O., et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010, 77:247-255.
36. Tielemans C.L., Vlasak J., Kosa D., Billiouw J.M., Verpooten G.A., Mezei I., et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011, 29:1159-1166.